# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td>1.1 DEFINITION</td>
<td>1</td>
</tr>
<tr>
<td>2 GOOD CLINICAL PRACTICE</td>
<td>2</td>
</tr>
<tr>
<td>3 INCENTIVES</td>
<td>3</td>
</tr>
<tr>
<td>4 REGISTRATION OF A CONTRACT RESEARCH ORGANISATION</td>
<td>3</td>
</tr>
<tr>
<td>4.1 DOCUMENTS REQUIRED</td>
<td>3</td>
</tr>
<tr>
<td>4.2 APPLICATION FEES</td>
<td>5</td>
</tr>
<tr>
<td>5 CLINICAL TRIAL LICENCE</td>
<td>5</td>
</tr>
<tr>
<td>5.1 APPLICATION PROCESS FOR A CLINICAL TRIAL LICENCE</td>
<td>5</td>
</tr>
<tr>
<td>5.2 SPONSOR</td>
<td>6</td>
</tr>
<tr>
<td>5.3 APPLICATION FEES (MEDICINAL PRODUCTS)</td>
<td>7</td>
</tr>
<tr>
<td>6 PROGRESS AND COMPLETION OF CLINICAL TRIAL REPORT</td>
<td>7</td>
</tr>
<tr>
<td>7 COMPLETION AND DISCONTINUANCE OF CLINICAL TRIAL</td>
<td>7</td>
</tr>
<tr>
<td>8 CLASSIFICATION OF MEDICAL DEVICES</td>
<td>8</td>
</tr>
<tr>
<td>8.1 NON-INVASIVE</td>
<td>9</td>
</tr>
<tr>
<td>8.2 INVASIVE DEVICES</td>
<td>10</td>
</tr>
<tr>
<td>8.3 SURGICALLY INVASIVE DEVICES</td>
<td>11</td>
</tr>
<tr>
<td>8.4 SURGICALLY INVASIVE DEVICES (SHORT-TERM)</td>
<td>12</td>
</tr>
<tr>
<td>8.5 SURGICALLY INVASIVE DEVICES (LONG-TERM)</td>
<td>13</td>
</tr>
<tr>
<td>8.6 ACTIVE DEVICES</td>
<td>14</td>
</tr>
<tr>
<td>8.7 APPLICATION FEES</td>
<td>15</td>
</tr>
<tr>
<td>9 CLEARANCE OF SAMPLES AND OTHER MATERIALS FOR RESEARCH PURPOSES</td>
<td>16</td>
</tr>
<tr>
<td>10 CONTACTS</td>
<td>17</td>
</tr>
<tr>
<td>10.1 INSTITUTIONS / REGULATORY BODIES</td>
<td>17</td>
</tr>
<tr>
<td>10.2 CONTRACT RESEARCH ORGANIZATIONS</td>
<td>18</td>
</tr>
</tbody>
</table>
1 Introduction

The promulgation of the Clinical Trial Act 2011 has paved the way for the development of the life sciences sector. The Act provides the legal framework for the conduct of clinical trials. These clinical research work can provide solutions to a broad range of genetic, infectious and lifestyle diseases like diabetes, cardiovascular diseases, cancer, hypertension amongst others prevailing in Mauritius and countries of the region.

1.1 Definition

“Clinical trial” means an investigation in a subject intended to:

(a) discover or verify the clinical or pharmacological effect of an investigational medicinal product;
(b) identify any adverse reaction to such a product; or
(c) study the absorption, distribution, metabolism and excretion of such a product, for the purpose of ascertaining the safety or efficacy of the product, after its administration to the subject;

The Mauritian government has identified life sciences and clinical trial as a promising sector for Mauritius and appropriate legislation has been introduced with a view to encourage the development of this sector.

The Clinical Trials Act provides for the setting up of the Clinical Research Regulatory Council, Ethics Committee and the Pharmacovigilance Committee.

The CRRC is mandated by law, inter alia, to:

- Consider and grant or refuse applications for a trial licence;
- Issue, amend, extend, review, suspend or cancel trial licences;
- Examine and approve the qualifications of every investigator;
- Exercise control over licensees and on sites by inspection and examination of any reports received
- Consult regularly with, and consider reports and recommendations from, the Ethics Committee, the Pharmacovigilance Committee and the Trade and Therapeutics Committee.
The CRRC is additionally responsible for the registration of CROs and the regulation and control of trial licenses which are issued.

As at date, there are 5 Contract Research Organisations (CROs) based in Mauritius. These CROs are carrying various clinical trials on a number of diseases such as diabetes, HIV, hepatitis, amongst others and are leading to knowledge transfer and job creation. Also fuelling the trend is a multi-ethnic, drug naive population and ageing population which presents enormous opportunities to position Mauritius as a hub for clinical trial for the region.

2 Good Clinical Practice

Clinical trials shall be conducted in accordance with the conditions and principles of good clinical practice. In this respect, the below mentioned rule must be followed:

- The rights, safety and well-being of a subject shall prevail over the interests of science and society.
- Every sponsor shall ensure that any person involved in conducting a clinical trial is qualified by education, training and experience to perform his tasks.
- Every sponsor and investigator shall comply with guidelines prepared or approved by the Council.

The Clinical Research Regulatory Council and Ethics Committee are abiding to the ICH European Guidelines to permit the conduct of Clinical Research in Mauritius:

3 Incentives

The table below lists the incentives applicable to companies engaged in clinical research and testing activities:

<table>
<thead>
<tr>
<th>Activity</th>
<th>Incentives</th>
</tr>
</thead>
</table>
| Life Sciences     | • 8-year income tax holiday on income derived from healthcare, biotechnology and life sciences from year of incorporation  
                     • VAT exemption on construction of medical Research & Development centers  
                     • VAT exemption on plants and equipment  
                     • Accelerated depreciation of 50% in respect of capital expenditure incurred on Research & Development, that is the investment cost is fully amortised in 2 years  
                     • Exemption of registration duty on acquisition of immovable property  
                     • Double deduction in respect of qualifying expenditure on R&D directly related to the entity’s trade or business and provided the R&D is carried out in Mauritius. |

Table 1: Incentives for Life Sciences sector

4 Registration of a Contract Research Organisation

The Clinical Trials (Registration of Contract Research Organisations) Regulations 2021 made under section 35 of the Clinical Trial Act took effect from 29 March 2021. It establishes the registration process for Contract Research Organisation (CROs) before undertaking any clinical trials in Mauritius. Under these regulations, application by a CRO must be made with the Council at least 2 months prior to the commencement of its activities.

The Regulations provide for a list of a user-friendly documents that must be submitted to the Council with an application form, including both for the organisation as a whole and individually for staff. Once the Council approves the registration, a Certificate is issued to the CRO.

4.1 Documents Required

4.1.1 Applicant

1. Certified copy of the Certificate of Incorporation
2. Certificate of Current Standing
3. Corporate Profile, Latest Annual Return and Audited Financial Statements
4. Organigram
5. Floor Plan of Research Offices (demonstrate adequate equipment and infrastructure)
6. Fire Certificate
7. Evidence of compliance to Good Clinical Practice and other relevant trainings
8. Certificates of Insurance (public liability, professional indemnity, cyber protection)
9. ISO Certification
10. Procedures for dealing with non-compliances
11. Adequate Standard Operating Procedures and associated documents (templates and forms)
12. Relevant policies as per the law
13. Quality Management Plan
14. Business Continuity Plan
15. Adequate IT systems
16. Good Data Handling policies (including compliance with Data Protection Act 2017)
17. Confidentiality Procedures in place
18. Provision for Pharmacovigilance (system in place for safe reporting)

4.1.2 Others

Person in Charge
1. Curriculum Vitae
2. Certificates
3. Evidence that the Person in Charge complies with the requirements of paragraph 2 (1) of the Guidelines for Contract Research Organization
4. Minimum of 5 years’ experience in clinical research field

Investigator
1. Curriculum Vitae
2. Certificates
3. Evidence of Registration with the Medical Council of Mauritius
4. Evidence of Fitness to practice
5. Minimum of 5 years’ experience in clinical research field

Medical Practitioner
1. Curriculum Vitae
2. Certificates
3. Evidence of Registration with the Medical Council of Mauritius
4. Certificate of good standing from the Medical Council of Mauritius
### 4.2 Application Fees

<table>
<thead>
<tr>
<th>Service</th>
<th>Fee (MUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration of CRO</td>
<td>50,000</td>
</tr>
<tr>
<td>Application for extension of certificate of CRO</td>
<td>25,000</td>
</tr>
<tr>
<td>Inspection Fee</td>
<td>5,000</td>
</tr>
</tbody>
</table>

### 5 Clinical Trial Licence

The application of a Clinical Trial Licence is governed by section 12 of the Clinical Trials Act.

The application for the Trial Licence must be made with the Council and accompanied by the prescribed fee and relevant documents.

#### 5.1 Application Process for a Clinical Trial Licence

**Figure 1: Main steps for the issue of a Clinical Trial Licence**

As per section 12 of the Clinical Trials Act 2011, an application for a Trial Licence should be accompanied by the application fee and the following documents:

- Protocol;
- An investigator’s brochure;
- Brief CV and proof of registration with the medical council for each investigator;
- Proof of registration with other regulatory bodies, if applicable;
• A GMP certificate and a Certificate of Pharmaceutical Product (COPP) in relation to every investigational product or device from the country of origin;
• Bilingual forms to be used for the purpose of patient/subject information, informed consent, recruitment of subjects, adverse event reports and adverse reaction reports; and
• Proof of local insurance coverage.

5.2 Sponsor
The sponsor shall also provide:

• information as to the quantity of every investigational medicinal product to be used in the clinical trial;
• Information relating to the measures to be taken for the health, welfare, safety and protection of subjects;
• Information relating to the financial aspects of the clinical trial, in particular:
  (i) Sources of funding for the clinical trial and information on the financial or other interests of the sponsor relevant to the clinical trial;
  (ii) The arrangements for the reimbursement of expenses incurred by the subjects;
  (iii) Any provision for compensation in the event of injury or death resulting from the clinical trial, including details of any insurance cover to be contracted for the protection of subjects;
  (iv) Details of any insurance or indemnity to cover the liability of the sponsor and investigator; and
  (v) Summary details of any financial arrangements between:

(A) the sponsor and the investigator; and

(B) the sponsor and the owner or occupier of the site;

• Information relating to the anticipated benefits and risks of the clinical trial;
• Information relating to the location, structure and amenities of any site where the clinical trial is to be conducted; and
• Such other information as the Council may require.

Upon submission of all relevant documents and information for the issue of a clinical trial licence, the Council shall within a period of 30 working days proceed with the determination of the application.
5.3 Application Fees (Medicinal Products)

<table>
<thead>
<tr>
<th>Service</th>
<th>Fee (MUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Fee</td>
<td>10,000</td>
</tr>
<tr>
<td>Fee payable for the issue of an amended licence</td>
<td>20,000</td>
</tr>
<tr>
<td>Clinical trial (Phase I) licence</td>
<td>100,000</td>
</tr>
<tr>
<td>Clinical trial (Phase II with a known product) licence</td>
<td>150,000</td>
</tr>
<tr>
<td>Clinical trial (Phase II with an unknown product) licence</td>
<td>200,000</td>
</tr>
<tr>
<td>Clinical trial (Phase III with a known product) licence</td>
<td>150,000</td>
</tr>
<tr>
<td>Clinical trial (Phase III with an unknown product) licence</td>
<td>200,000</td>
</tr>
<tr>
<td>Clinical trial (Phase IV) license</td>
<td>20,000</td>
</tr>
<tr>
<td>Annual Service Fee</td>
<td>20,000</td>
</tr>
</tbody>
</table>

Clinical Trials (Licence and Fees) Regulations 2011

6 Progress and Completion of Clinical Trial Report

Every sponsor shall furnish to the Council a written report on the progress of a clinical trial, containing such particulars as the Council deems necessary, not later than 6 months after:

- the date on which the trial license is issued;
- the end of every subsequent period of 6 months; and
- the completion of the clinical trial.

7 Completion and Discontinuance of Clinical Trial

A sponsor shall, not later than 90 days after a clinical trial is completed, notify the Council of the completion.

Where a clinical trial is discontinued, its sponsor shall forthwith notify the Council in writing of the discontinuance and the reasons thereof.
8 Classification of Medical Devices

The Clinical Trials (Medical Devices Trials) Regulations was introduced in 2021 under section 35 of the Clinical Trial Act and caters for the provision of medical devices trials.

Under these regulations, trials must be authorized together with the process of licensing a trial and payment of relevant fee. The regulations also mention specific rules on device classification.

In line with the Clinical Trials (Medical Devices Trials) Regulations 2021, the following apply:

- No person shall conduct a clinical trial in respect of a medical device unless he is registered with the Council for this purpose;
- Any person who intends to conduct clinical trials in respect of a medical device shall make an application for a trial licence to the Council;
- Application form and documents to be submitted as per requirements of the Council;
- Full details of Rules and Classification are available in the Regulations.
8.1 Non-Invasive

Reference is made to the Clinical Trials (Medical Devices Trials) Regulations (https://www.edbmauritius.org/sites/default/files/2022-08/medical%20devices%20trials%20regulations.pdf)
8.2 invasive Devices

CLASSIFICATION OF DEVICES
Invasive Devices

- Invasive Devices
  - RULE 5
  - (in body orifice or stoma)

- Transient Use
  - Class I

- Short-term Use
  - Class IIa
  - For use with blood, other blood fluids, organs, tissues

- Long-term Use
  - Class IIb
  - Only filtration, centrifugation or exchange of gas or heat

- Connected to an active medical device in Class IIa or higher
  - Class IIa
8.3 Surgically Invasive Devices

CLASSIFICATION OF DEVICES
Surgically Invasive Devices

- Class IIa
  - Surgically Invasive Devices RULE 6
    - Control/Diagnose/monitor/correct a defect of the heart or the circulatory system through direct contact
    - Direct contact with the circulatory system and central nervous system
    - Reusable surgical instrument
    - Biological effect-mainly or wholly absorbed
    - Intended to administer medicinal products in a potentially hazardous manner

  - Class IIb
    - Class IIb
  - Class I

Class III
Class III
Class III

11
8.4 Surgically invasive Devices (Short-Term)

CLASSIFICATION OF DEVICES
Surgically Invasive Devices (Short-Term)

- Class III: Control/Diagnose/ Monitor/Correct a defect of the heart or the circulatory system through direct contact
- Class III: Direct Contact with circulatory system and central nervous system
- Class IIb: Undergo chemical change in body (NOT in teeth)
- Class III: Biological effect-mainly or wholly absorbed
- Class IIb: Intended to administer medicinal products in a potentially hazardous manner
8.5 Surgically Invasive Devices (Long-Term)

CLASSIFICATION OF DEVICES
Surgically Invasive Devices (Long-term)

- **Class IIa**: To be placed in teeth
- **Class III**: Direct contact with circulatory system and central nervous system
- **Class III**: Undergo chemical change in body (NOT in teeth)
- **Class III**: Intended to administer medicinal products in a potentially hazardous manner
- **Class III**: Active implantable devices
- **Class III**: Breast implants, total or partial joint replacements, spinal disc replacement
8.6 Active Devices

CLASSIFICATION OF DEVICES
Active Devices

Class Ia
- Rule 9a: Active therapeutic devices intended to administer or exchange energy
- Administer or exchange energy in potentially hazardous way

Class Iib
- Intended to control/monitor or influence directly the performance of a class III active therapeutic device

Class IIa
- Rule 10: Active devices for diagnosis and monitoring
- Devices intended to illuminate patient’s body in the visible spectrum

Class IIa
- Rule 11: Active devices to administer or remove medicines & other substances from the body
- Specifically intended to monitor vital physiological parameters
- Potentially hazardous

Class I
- All other active devices

Class Iib
## 8.7 Application Fees

<table>
<thead>
<tr>
<th>Type of License</th>
<th>Rs</th>
<th>PILOT STUDY</th>
<th>PIVOTAL STUDY</th>
<th>POST APPROVAL STUDY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issue of trial license</td>
<td>10,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Issue of amended trial license</td>
<td>20,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Issue of duplicate license</td>
<td>10,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual service fee</td>
<td>20,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class I medical device with low risk</td>
<td>10,000</td>
<td>20,000</td>
<td>10,000</td>
<td></td>
</tr>
<tr>
<td>Class IIa medical device</td>
<td>20,000</td>
<td>40,000</td>
<td>20,000</td>
<td></td>
</tr>
<tr>
<td>Class IIb medical device with moderate risk</td>
<td>40,000</td>
<td>80,000</td>
<td>40,000</td>
<td></td>
</tr>
<tr>
<td>Class III medical device with high risk</td>
<td>100,000</td>
<td>200,000</td>
<td>75,000</td>
<td></td>
</tr>
</tbody>
</table>
9 Clearance of Samples and other materials for research purposes

Procedures prior to receipt of samples

The following steps are required for clearance of samples:

1. Submission of an official request to the Director Pharmaceutical Services (DPhS), Ministry of Health and Wellness, for import authorization of products for clinical research purposes.

2. Request for import authorization

   Submission of the following documents (first time applicant):

   • Approval from Clinical Research Regulatory Authority & Ethics Committee
   • Trial Licence
   • Brief of Applicant

3. Submission of request for clearance in 3 copies (one to be kept by the Pharmacy Department and remaining two to be returned to the applicant after approval by the Pharmacy section).

4. Issuance of approval by the DPhS and same to be issued by the Deputy Director Pharmaceutical Services (DDPhS) in his absence.

5. List of pharmacists posted at point of entries will be submitted to applicant upon request. However, this list may change at any time.

6. Issuance of authorisation for import by the Pharmacy Department (either on the same day or within one day after request).
10 Contacts

10.1 Institutions / Regulatory Bodies

Economic Development Board
BIO Industry & Project Development
Tel: +230 203 3800
Email: bpd@edb mauritius.org

Clinical Research Regulatory Council
Tel: + 230 214 3972
Email: crrc@govmu.org

Pharmacy Board
Directorate of the Pharmacy Board
Tel: +230 201 1334
Email: moh-pharm@govmu.org

Customs Department
Tel: +230 202 0500
Email: customs@mra.mu
## 10.2 Contract Research Organizations

<table>
<thead>
<tr>
<th>Name of Company</th>
<th>Telephone No.</th>
<th>Email</th>
<th>Contact Person</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap Research Ltd</td>
<td>+2304602144</td>
<td><a href="mailto:regine.rouzier@cap-research.com">regine.rouzier@cap-research.com</a></td>
<td>Dr Regine Rouzier Chief Executive Officer</td>
</tr>
<tr>
<td>Centre D'Etudes Cliniques Ltee</td>
<td>+2302141405</td>
<td><a href="mailto:sadiyah.joomun@centredetudescliniques.com">sadiyah.joomun@centredetudescliniques.com</a></td>
<td>Mrs Sadiyah Joomun Operations Manager</td>
</tr>
<tr>
<td>Centre International De Developpement Pharmaceutique Ltee</td>
<td>+230 4012600</td>
<td><a href="mailto:c.blazy@cidp-cro.com">c.blazy@cidp-cro.com</a></td>
<td>Mrs Claire Blazy-Jauzac Chief Executive Officer</td>
</tr>
<tr>
<td>Clinear Research Ltd</td>
<td>+230 59097635</td>
<td><a href="mailto:lutchmee.nobaub@gmail.com">lutchmee.nobaub@gmail.com</a></td>
<td>Mrs Lutchmee Nobaub Chief Executive Officer</td>
</tr>
<tr>
<td>Insight Research</td>
<td>+230 4670231</td>
<td><a href="mailto:dso@insight-research.com">dso@insight-research.com</a></td>
<td>Mr Deyna Soobben Managing Director</td>
</tr>
</tbody>
</table>

**Disclaimer**

Whilst care has been taken to ensure that the information provided herein is accurate and correct, at the time of publication, users of this publication are advised to seek guidance from the Economic Development Board in case of uncertainty or ambiguity encountered in reading. The Economic Development Board shall, in no circumstances whatsoever, be held liable to any person arising from use of information contained herein.